This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer.

NCT07249879 · clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
55
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Collaborators